{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015516","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.012410+00:00","generated_at":"2026-05-19T03:00:16.815391+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1","bullets":["Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.","Accumulated deficit $960,013; cash and cash equivalents $1.","Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.","Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.","Going concern uncertainty: company has not commenced commercial operations and expects further losses."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015516","json":"https://secwatch.observer/filing/0001641172-25-015516.json","markdown":"https://secwatch.observer/filing/0001641172-25-015516.md","text":"https://secwatch.observer/filing/0001641172-25-015516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/0001641172-25-015516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T03:00:16.815391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}